ERBB2 and breast cancer: Likewise, HER2+ tumors can be treated with antibodies or kinase inhibitors targeting HER2 signaling (i.e., Trastuzamab and Lapatinib) and are often met with success provided the disease is caught early; the efficacy of these therapies drastically decreases with late stage, metastatic HER2+ BC[20–23].